Výsledky vyhledávání

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin

Autor: Maki Goda, Nobuya Inagaki, Peter A. Crawford, Hiroaki Iijima, David Polidori, Nobuko Maruyama

Publikováno v: Diabetes, Obesity & Metabolism

Sodium glucose co-transporter 2 (SGLT2) inhibitors have been associated with increased serum ketone body levels in patients with type 2 diabetes mellitus (T2DM). In the present analysis we evaluated serum ketone body levels and variability in 1278 Ja

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a93dad35a931b0683a95fbb41eab13
https://doi.org/10.1111/dom.13224

Zobrazit plný text záznamu

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

Autor: Nobuko Maruyama, Nobuya Inagaki, Maki Goda, Shoko Yokota, Hiroaki Iijima

Publikováno v: Advances in Therapy

Introduction Sodium glucose co-transporter 2 inhibitors decrease hemoglobin A1c (HbA1c) and blood pressure (BP) and slightly increase low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus (T2DM). The effects of baselin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::386f35068acdea426f4ce219704bb80d
https://doi.org/10.1007/s12325-015-0255-8

Zobrazit plný text záznamu

Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan

Autor: Maki Goda, Kazuyo Sasaki, Takumi Tajima, Tomoko Yamakura, Makoto Ueno

Publikováno v: Current medical research and opinion. 34(2)

To evaluate the safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus (T2DM) in clinical settings.The authors conducted a 1-year post-marketing surveillance (PMS) of canagliflozin in almost all the elderly patients (�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c44306e8383b77384c2428f518aca8c
https://pubmed.ncbi.nlm.nih.gov/29025285

Zobrazit plný text záznamu

Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study

Autor: Maki Goda, Nobuko Maruyama, Shoko Yokota, Nobuya Inagaki, Hiroaki Iijima

Publikováno v: Expert opinion on pharmacotherapy. 16(11)

The safety and efficacy of sodium glucose co-transporter 2 inhibitors in non-obese compared with obese patients with type 2 diabetes mellitus is unknown.We conducted post hoc analyses of the results of a 52-week open-label study of Japanese type 2 di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef3c5daacd8be033d6ffc87e24c70b6f
https://pubmed.ncbi.nlm.nih.gov/26104600

Zobrazit plný text záznamu

Sodium iodoacetate-induced experimental osteoarthritis and associated pain model in rats

Autor: Rei Imaizumi, Atsushi Fukunari, Hideki Tanaka, Kiyoshi Kobayashi, Hiroshi Sumichika, Hirotsugu Komatsu, Maki Goda

Publikováno v: The Journal of veterinary medical science. 65(11)

Degenerative lesions were induced in the knee joint of Wistar rats by intraarticular injection of chondrocyte metabolism inhibitor mono-iodoacetate (MIA) at doses of 0, 0.3 or 3 mg/joint. Histopathological examination and the measurement of hind paw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d229f65165be041c9092b7f6bac45061
https://pubmed.ncbi.nlm.nih.gov/14665748

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání